SCHEMBL1011709

SCHEMBL1011709

O=Cc1ccc2cccnc2c1[N+](=O)[O-]

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.53
ERN1 O75460 1/20 0.46
MAPT P10636 5/20 0.46
LMNA P02545 3/20 0.46
KDM4E B2RXH2 3/20 0.46
HSP90AA1 P07900 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
NFKB1 P19838 2/20 0.46
HTT P42858 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
GMNN O75496 1/20 0.46
TP53 P04637 1/20 0.46
MMP2 P08253 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
MMP9 P14780 1/20 0.46
ALOX15 P16050 1/20 0.46
TSHR P16473 1/20 0.46
MMP8 P22894 1/20 0.46
CCR1 P32246 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18434428 0.86 PDE10A (0.51) PDE10AERN1MAPTLMNAKDM4E
SCHEMBL31570753 0.86 PDE10A (0.51) PDE10AMAPTLMNAKDM4EHSP90AA1
SCHEMBL1012510 0.80 PDE10A (0.46) PDE10AMAPTLMNAKDM4EHSP90AA1
SCHEMBL1012509 0.80 PDE10A (0.46) PDE10AMAPTLMNAKDM4EHSP90AA1
SCHEMBL1011432 0.78 TSHR (0.56) PDE10AMAPTLMNAKDM4EHSP90AA1
SCHEMBL10615047 0.78 PDE10A (0.56) PDE10AMAPTLMNAKDM4EHSP90AA1
SCHEMBL10690325 0.78 PDE10A (0.56) PDE10AMAPTLMNAKDM4EHSP90AA1
SCHEMBL2672220 0.78 MAPT (0.56) PDE10AERN1MAPTLMNAKDM4E
SCHEMBL10277488 0.78 PDE10A (0.56) PDE10AMAPTLMNAKDM4EHSP90AA1
SCHEMBL28105322 0.76 MEN1 (0.33) ERN1MAPTHTTTDP1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103492028-B Sulfonaminoquinoline hepcidin antagonists 维福(国际)股份公司 2017-02-08 CN disclosed
EP-2675526-B1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2017-02-01 EP disclosed
US-9102688-B2 Sulfonaminoquinoline hepcidin antagonists VIFOR (INTERNATIONAL) AG (CH) 2015-08-11 US disclosed
US-9102688-B2 Sulfonaminoquinoline hepcidin antagonists VIFOR (INTERNATIONAL) AG (CH) 2015-08-11 US disclosed
US-9102688-B2 Sulfonaminoquinoline hepcidin antagonists VIFOR (INTERNATIONAL) AG (CH) 2015-08-11 US disclosed
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2014-12-11 US disclosed
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2014-12-11 US disclosed
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2014-12-11 US disclosed
CN-103492028-A Novel sulfonaminoquinoline hepcidin antagonists VIFOR INT AG 2014-01-01 CN disclosed
EP-2675526-A1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS Vifor (International) AG (CH) 2013-12-25 EP disclosed
WO-2007064484-A2 ELECTROLUMINESCENT DEVICE CONTAINING A PHENANTHROLINE DERIVATIVE EASTMAN KODAK COMPANY (US) 2007-06-07 WO disclosed
WO-2007064484-A2 ELECTROLUMINESCENT DEVICE CONTAINING A PHENANTHROLINE DERIVATIVE EASTMAN KODAK COMPANY (US) 2007-06-07 WO disclosed
WO-2007064493-A1 ELECTROLUMINESCENT DEVICE CONTAINING AN ANTHRACENE DERIVATIVE EASTMAN KODAK COMPANY (US) 2007-06-07 WO disclosed
WO-2007064493-A1 ELECTROLUMINESCENT DEVICE CONTAINING AN ANTHRACENE DERIVATIVE EASTMAN KODAK COMPANY (US) 2007-06-07 WO disclosed
US-20070122656-A1 Electroluminescent device containing an anthracene derivative EASTMAN KODAK COMPANY 2007-05-31 US disclosed
US-20070122656-A1 Electroluminescent device containing an anthracene derivative EASTMAN KODAK COMPANY 2007-05-31 US disclosed
US-20070122656-A1 Electroluminescent device containing an anthracene derivative EASTMAN KODAK COMPANY 2007-05-31 US disclosed
US-20070122657-A1 Electroluminescent device containing a phenanthroline derivative EASTMAN KODAK COMPANY 2007-05-31 US disclosed
US-20070122657-A1 Electroluminescent device containing a phenanthroline derivative EASTMAN KODAK COMPANY 2007-05-31 US disclosed
US-20070122657-A1 Electroluminescent device containing a phenanthroline derivative EASTMAN KODAK COMPANY 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 PDE10A 3260/4885ERN1 2314/4885MAPT 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.